Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901694 | 1.00 | ALDH1A1 (0.48) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL12525034 | 1.00 | ALDH1A1 (0.48) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL18590503 | 0.83 | MAPT (0.42) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL18590507 | 0.83 | MAPT (0.42) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL18590508 | 0.83 | MAPT (0.42) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL18590502 | 0.83 | MAPT (0.42) | ALDH1A1NPSR1BRD4CREBBPLMNA | |
| SCHEMBL6482507 | 0.81 | SLC6A3 (0.45) | ALDH1A1LMNAGAA | |
| SCHEMBL20131339 | 0.81 | DDB1 (0.46) | ALDH1A1LMNASMN1; SMN2ADORA3 | |
| SCHEMBL6482499 | 0.81 | SLC6A3 (0.45) | ALDH1A1LMNAGAA | |
| SCHEMBL6482502 | 0.81 | SLC6A3 (0.45) | ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694474-A1 | 4R,5R-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | Grindeks (LV) | 2014-02-12 | — | — | EP | claimed |
| WO-2012123358-A1 | 4R,5R-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS (LV) | 2012-09-20 | — | — | WO | claimed |
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2014-10-02 | — | — | US | disclosed |
| US-8791273-B2 | 4R,5S-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity | JSC GRINDEKS (LV) | 2014-07-29 | — | — | US | disclosed |
| EP-2694474-A1 | 4R,5R-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | Grindeks (LV) | 2014-02-12 | — | — | EP | disclosed |
| EP-2496555-B1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS JSC (LV) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012123358-A1 | 4R,5R-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS (LV) | 2012-09-20 | — | — | WO | disclosed |
| EP-2496555-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | Grindeks, A Joint Stock Company (LV) | 2012-09-12 | — | — | EP | disclosed |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | JSC GRINDEKS (LV) | 2012-08-23 | — | — | US | disclosed |
| WO-2011054888-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296317-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | ALDH1A1 716/4885NPSR1 414/4885BRD4 366/4885 |
| US-20120215010-A1 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY | NAAA, NAT1, NAA15 | ALDH1A1 716/4885NPSR1 414/4885BRD4 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.